JN 304
Alternative Names: JN-304; KB-304Latest Information Update: 06 Apr 2023
At a glance
- Originator Krystal Biotech
- Developer Jeune; Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Collagen replacements; Extracellular matrix protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Skin disorders